TeamDrive
RUS

Company

Team Drive was founded in 2011 as the brainchild of two of Russia’s most successful and prominent business leaders, Leonid Melamed (ex-CEO of Sistema JSFC*, Russia’s largest publically traded holding, and previously CEO of Rosno, Russia’s largest insurer and MTS, Russia’s largest telecommunications operator) and Vladimir Gurdus (ex-CEO of Medsi, Russia’s largest private healthcare provider). 

Having spent two decades successfully conceiving, building, operating and exiting  multi-billion-dollar brands and businesses in Russia and the CIS, Leonid and Vladimir came to the conclusion that not only could Russian assets and businesses be created that were highly competitive in Russia, but highly competitive at global scale, with concomitant returns to equity. In other words, that Russian assets, capital, talent, ideas, companies and brands represent a vast and largely untapped reservoir of investor and customer value potential, both in a Russian market context as well as in a global market context. Team Drive was created specifically to unlock this untapped value potential.

We offer an end-to-end asset management and value augmentation service in Russia with a focus on distressed or underperforming assets going all the way from initial control, creditor/investor alignment, goals/objectives definition, detailed brand and market differentiation strategy to business planning, operational execution and optimal exit, operating to global best practices. 


*Sistema JSFC is the largest publicly-traded diversified holding company in Russia and the CIS. Incorporated in 1993, Sistema is now one of Russia's top ten companies by revenues and is one of the largest investment companies in the world. The group owns a diverse set of public and private companies, which it holds in two distinct portfolios.

Media Center

  • 20 September 2017

    India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

    India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

    Zydus Cadila, an Indian injectables maker, said it reached a deal with Russia’s Pharm Aid to manufacture its varicella vaccine for the Russian Federation. The Russians have been pressuring foreign pharmaceutical companies to engage in local production if they want to be in its market. Earlier this year, Russia-based NovaMedica announced it began work on a new plant in Russia’s Kaluga region where it will produce 30 of Pfizer’s sterile injected generic medications for the local market.

  • 19 September 2017

    Clinical trials of drugs for autoimmune diseases and cancer soon to start in Russia

    Clinical trials of about 30 new medicinal products for the treatment of cancer, autoimmune and hereditary diseases are expected to start in the Russian Federation. This was announced by the Russian Minister of Health Veronika Skvortsova at Biotechmed, a specialized conference.

  • 19 September 2017

    Kazakhstan plans a phased introduction of regulated prices for all drugs

    The Ministry of Health of the Republic of Kazakhstan elaborated a draft Law of the Republic of Kazakhstan “On Changes and Amendments to Certain Legislative Acts of the Republic of Kazakhstan on the Issues of Circulation of Medicines and Medical Devices” in order to improve the regulation in this area and create a patient-oriented drug provision model.

  • 18 September 2017

    Yakutia team aims to keep degenerative brain disease at bay

    Scientists at the North-Eastern Federal University in Yakutsk (NEFU), in Russia’s Far East, have developed a method of alleviating symptoms and slowing down the progression of spinocerebellar ataxia, or atrophy, an acute genetic brain disease that leads to dramatic motor coordination impairment and eventual shortening of a patient’s life expectancy. 

Read more